View on Pubmed.gov 27993855 | View on doi.org 10.1128/AAC.022...
Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments.
- Department of Food and Environmental Sciences, University of Helsinki, Helsinki, Finland finny.varghese@radboudumc.nl tero.ahola@helsinki.fi.
- Institute of Technology, University of Tartu, Tartu, Estonia.
- Department of Virology, University of Turku, Turku, Finland.
- Institute of Virology, University of Bonn Medical Centre, Bonn, Germany.
Abstract
As new pathogenic viruses continue to emerge, it is paramount to have intervention strategies that target a common denominator in these pathogens. The fusion of viral and cellular membranes during viral entry is one such process that is used by many pathogenic viruses, including chikungunya virus, West Nile virus, and influenza virus. Obatoclax, a small-molecule antagonist of the Bcl-2 family of proteins, was previously determined to have activity against influenza A virus and also Sindbis virus. Here, we report it to be active against alphaviruses, like chikungunya virus (50% effective concentration [EC] = 0.03 μM) and Semliki Forest virus (SFV; EC = 0.11 μM). Obatoclax inhibited viral entry processes in an SFV temperature-sensitive mutant entry assay. A neutral red retention assay revealed that obatoclax induces the rapid neutralization of the acidic environment of endolysosomal vesicles and thereby most likely inhibits viral fusion. Characterization of escape mutants revealed that the L369I mutation in the SFV E1 fusion protein was sufficient to confer partial resistance against obatoclax. Other inhibitors that target the Bcl-2 family of antiapoptotic proteins inhibited neither viral entry nor endolysosomal acidification, suggesting that the antiviral mechanism of obatoclax does not depend on its anticancer targets. Obatoclax inhibited the growth of flaviviruses, like Zika virus, West Nile virus, and yellow fever virus, which require low pH for fusion, but not that of pH-independent picornaviruses, like coxsackievirus A9, echovirus 6, and echovirus 7. In conclusion, obatoclax is a novel inhibitor of endosomal acidification that prevents viral fusion and that could be pursued as a potential broad-spectrum antiviral candidate.
References
Antiviral Res. 2016 Feb;126:117-24
Antiviral Res. 2016 Nov;135:81-90
Annu Rev Virol. 2014 Nov;1(1):171-89
Antiviral Res. 2010 Aug;87(2):111-24
Cited by 65 citations (total)
Journal Article Research Support, Non-U.S. Gov't Review
Antivirals against Chikungunya Virus: Is the Solution in Nature?
Electronic publication date February 23, 2021
Daniel Oliveira Silva Martins [...] Ana Carolina Gomes Jardim et al.
The worldwide outbreaks of the chikungunya virus (CHIKV) in the last years demonstrated the need for studies to screen antivirals...
Journal Article Research Support, N.I.H., Extramural Review
A molecular understanding of alphavirus entry.
Electronic publication date January 1, 2021
Autumn C Holmes [...] Michael S Diamond et al.
Alphaviruses cause severe human illnesses including persistent arthritis and fatal encephalitis. As alphavirus entry into target cells is the first...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •
Copyright
Copyright © 2017 American Society for Microbiology.